Unchained Labs Acquires Blacktrace Group from Maven

The Carlyle Group Acquires Unchained Labs

April 26, 2021

Medical Devices

The Carlyle Group agreed to acquire life sciences tools company Unchained Labs for $435 million from Novo Holdings A/S, Canaan Partners and TPG Biotech, in a transaction expected to close in Q2 2021. Carlyle will partner with Unchained Labs' management to accelerate organic and inorganic growth through investments in R&D, digitization and geographic expansion; Unchained is headquartered in Pleasanton, California and had ~170 employees and ~$75M revenue projected for 2021.

Unchained Labs Acquires NanoView Biosciences

May 4, 2022

Biotechnology

Unchained Labs, a life-sciences tools company based in Pleasanton, California, acquired NanoView Biosciences to add exosome and viral-vector characterization technologies (ExoView and LentiView) to its product portfolio. The acquisition expands Unchained Labs' capabilities for gene therapy and biologics researchers by integrating NanoView's microchip-based interferometry and fluorescence platforms.

908 Devices Acquires TRACE Analytics GmbH

August 9, 2022

Medical Devices

908 Devices (Nasdaq: MASS) has completed the acquisition of TRACE Analytics GmbH, a Braunschweig, Germany-based provider of on-line aseptic sampling systems and biosensors for bioreactor monitoring. The purchase consideration includes $15.3 million in cash up front plus up to $2.0 million of contingent consideration, and 908 Devices says the acquisition will enable its mass spec devices to perform on-line bioprocess monitoring and advance its bioanalytics platform.

AbbVie Acquires Capstan Therapeutics

August 19, 2025

Biotechnology

AbbVie has completed its acquisition of Capstan Therapeutics, adding Capstan's lead asset CPTX2309 — an in vivo targeted lipid nanoparticle (tLNP) anti‑CD19 CAR‑T candidate in Phase 1 for B cell‑mediated autoimmune diseases — and a proprietary tLNP RNA delivery platform. The deal strengthens AbbVie's immunology pipeline and expands its in vivo cell‑programming capabilities for RNA payload delivery.

Danaher Acquires Precision NanoSystems

June 1, 2021

Biotechnology

Danaher Corporation has acquired Vancouver-based Precision NanoSystems (PNI), a developer of lipid nanoparticle delivery technologies and microfluidic manufacturing platforms for genetic medicines. PNI will join Danaher's Life Sciences platform to expand its capabilities in mRNA and genetic-medicine development and complement existing portfolio companies such as Cytiva and Pall.

Cell Microsystems Acquires Fluxion Biosciences

August 23, 2023

Medical Devices

Durham-based Cell Microsystems has acquired Fluxion Biosciences, adding Fluxion's IonFlux, BioFlux and IsoFlux instruments and services to its CellRaft-based product portfolio. The deal is supported by a concurrent Series B financing led by Telegraph Hill Partners to provide growth capital and accelerate product and service integration for cellular analysis and electrophysiology workflows.